CDKN2A and prostate cancer: Given the prevalence of alterations in androgen signaling in human prostate cancers, we generated R26hARL/wt:p16L/L:PB-Cre4 compound mice, in which conditional AR expression and p16Ink4a deletion co-occur in prostate epithelium (Fig 1D).